Leishmania donovani in hamsters: stimulation of non-specific resistance by novel lipopeptides and their effect in antileishmanial therapy

Experientia. 1995 Jul 14;51(7):725-30. doi: 10.1007/BF01941270.

Abstract

Several novel type of lipopeptides were synthesized and evaluated for their ability to stimulate non-specific resistance against Leishmania donovani infection. Peritoneal macrophages isolated from young male hamsters treated with muramyl dipeptide (MDP) and various synthetic lipopeptides (6 mg/kg i.p.) 7 days earlier, were cultured in vitro and challenged 24 h later with L. donovani promastigotes. One lipopeptide, Central Drug Research Institute (CDRI) compound 86/450, exhibited significantly higher immunostimulatory activity than MDP. Its prophylactic activity was further confirmed in hamsters by giving 2 split doses of 3 mg/kg of the compound spaced at 2 weeks, i.e. on day -7 and +7 of challenge with L. donovani amastigotes. The prophylactic effect lasted for 7 days following the last treatment with compound 86/450. The antileishmanial action of sodium stibogluconate (SAG) was also found to be enhanced by 16% in hamsters primed with compound 86/450.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • Adjuvants, Immunologic / therapeutic use*
  • Amino Acid Sequence
  • Animals
  • Cricetinae
  • Immunity, Innate / drug effects
  • Leishmania donovani / drug effects*
  • Leishmania donovani / immunology
  • Leishmaniasis, Visceral / drug therapy*
  • Leishmaniasis, Visceral / immunology
  • Male
  • Molecular Sequence Data
  • Oligopeptides / pharmacology
  • Oligopeptides / therapeutic use*

Substances

  • Adjuvants, Immunologic
  • Oligopeptides